ILP-2 (NT) Blocking Peptide

ILP-2 (NT) Blocking Peptide

Product No.: I-363

[product_table name="All Top" skus="I-363"]

- -
- -
Target
Inhibitor of Apoptosis Like Protein-2
Product Type
Blocking Peptide

- -
- -
Select Product Size
- -
- -

Antibody Details

Product Details

Reactive Species
Human
Product Concentration
0.2 mg/ml
Amino Acid Location
This peptide sequence is located at amino acids 2 to 13 of Human ILP-2 protein.
Formulation
This peptide is formulated in PBS pH 7.2 (0.01 M Sodium Phosphate, 0.13 M NaCl) containing 0.1% bovine serum albumin and 0.02% sodium azide.
Storage and Handling
Store this peptide in working aliquots at -20°C in a manual defrost freezer. Avoid Repeated Freeze Thaw Cycles.
Country of Origin
USA
Shipping
Next Day Ambient
Amino Acid Sequence
12 amino amino terminus of human ILP-2.
Each investigator should determine their own optimal working dilution for specific applications. See directions on lot specific datasheets, as information may periodically change.

Description

Background
Inhibitor of Apoptosis Like Protein-2 peptide is applicable as a control peptide for blocking antibody binding in Western blotting.

References & Citations

1. Inohara N, Koseki T, del Peso L, et al. Nod1, an Apaf-1-like activator of caspase-9 and nuclear factor-κB. J. Biol. Chem. 1999; 274:14560-7. 2. Ogura Y, Inohara N, Benito A, et al. Nod2, a Nod1/Apaf-1 family member that is restricted to monocytes and activates NF-κB. J. Biol. Chem. 2001; 276:4812-8. 3. Hugot JP, Chamaillard M, et al. Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease. Nature 2001; 411:599-603. 4. Ogura Y, Bonen DK, Inohara N, et al. A frameshift mutation in NOD2 associated with susceptibility to Crohn's disease. Nature 2001; 411:603-6.
- -
- -
Prod No.
Description
I-363
Disclaimer AlertProducts are for research use only. Not for use in diagnostic or therapeutic procedures.